| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $71,883,473 ) (Continued on the next page) |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01DA032581 | Incentive salience and the neuropsychological underpinnings of cue-induced smoking relapse | 000 | 7 | NIH | 4/27/2022 | $359,579 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA181196 | Studying metabolic stress signaling in renal cancer | 000 | 9 | NIH | 5/18/2022 | $339,350 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01NS087635 | Signal Transduction by alphavbeta8 Integrin | 001 | 8 | NIH | 4/12/2022 | $39,598 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01NS087635 | Signal Transduction by alphavbeta8 Integrin | 000 | 8 | NIH | 11/10/2021 | $356,402 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R37HD030284 | Female Reproductive Tract Development in the mouse | 000 | 29 | NIH | 6/3/2022 | $392,000 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA214749 | MSC-Derived Exosomes and MicroRNA in Glioma Therapy | 000 | 5 | NIH | 11/22/2021 | $329,400 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA214749 | MSC-Derived Exosomes and MicroRNA in Glioma Therapy | 001 | 5 | NIH | 5/20/2022 | $29,280 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA193297 | PAF-Remodeled DREAM Complex in Cancer and Regeneration | 000 | 8 | NIH | 4/20/2022 | $352,321 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01HL129795 | Controlling the core airway mucin secretion machinery to prevent pathophysiology | 000 | 7 | NIH | 3/16/2022 | $483,451 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01HL129795 | Controlling the core airway mucin secretion machinery to prevent pathophysiology | 001 | 7 | NIH | 6/15/2022 | $53,717 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | T32CA196561 | Interdisciplinary Translational Pre/Postdoctoral Program in Cancer Nanotechnology | 003 | 6 | NIH | 4/7/2022 | $326,346 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | T32CA196561 | Interdisciplinary Translational Pre/Postdoctoral Program in Cancer Nanotechnology | 002 | 6 | NIH | 4/6/2022 | $197,451 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01GM108908 | Regulation of chromatin organization and dynamics by INO80 | 000 | 7 | NIH | 1/5/2022 | $409,698 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01NS078152 | BK channel regulation by auxiliary LRR proteins | 000 | 10 | NIH | 5/11/2022 | $350,000 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA225701 | Strategies for Persistent Agitated Delirium in Palliative Care | 000 | 4 | NIH | 1/31/2022 | $398,923 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | P40OD024628 | Specific Pathogen Free Baboon Research Resource (SPFBRR) - Bridge Funding Administrative Supplement | 001 | 5 | NIH | 6/15/2022 | $900,000 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA216437 | 53BP1-dependent pathway in DNA repair | 000 | 6 | NIH | 5/19/2022 | $358,680 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA236864 | DELINEATING THE EVOLUTION AND ECOLOGY OF CHEMORESISTANCE IN BREAST CANCER WITH SINGLE CELL GENOMICS | 001 | 3 | NIH | 5/20/2022 | $29,647 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA236864 | DELINEATING THE EVOLUTION AND ECOLOGY OF CHEMORESISTANCE IN BREAST CANCER WITH SINGLE CELL GENOMICS | 000 | 3 | NIH | 11/19/2021 | $333,517 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA210929 | Define redundant functions of H2AX and NBS1 in DNA repair | 001 | 6 | NIH | 5/24/2022 | $29,280 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA210929 | Define redundant functions of H2AX and NBS1 in DNA repair | 000 | 6 | NIH | 12/23/2021 | $329,400 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | P01CA193124 | Processing and Repair of DNA Crosslinks | 001 | 6 | NIH | 5/19/2022 | $147,400 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | P01CA193124 | Processing and Repair of DNA Crosslinks | 000 | 6 | NIH | 2/1/2022 | $1,658,217 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA201380 | Identifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP Inactivation | 003 | 6 | NIH | 6/16/2022 | $0 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA201380 | Identifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP Inactivation | 001 | 6 | NIH | 4/26/2022 | $381,836 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA201380 | Identifying/Targeting Mechanisms of Lymphomagenesis Driven by CREBBP Inactivation | 002 | 6 | NIH | 4/27/2022 | $0 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA225647 | Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors, and Economic Implications | 001 | 4 | NIH | 5/19/2022 | $28,565 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA225647 | Targeted Oral Anticancer Agents: Patterns of Indicated and Off-Label Use, the Associated Factors, and Economic Implications | 000 | 4 | NIH | 12/8/2021 | $321,359 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA195524 | Early Detection of Hepatocellular Carcinoma | 001 | 6 | NIH | 4/21/2022 | $694,288 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA207295 | DNA damaging therapy and immune response in small cell lung cancer subtypes | 001 | 6 | NIH | 4/26/2022 | $387,250 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA225955 | Exploring Collateral Lethality for Development of Cancer Therapeutics | 001 | 5 | NIH | 5/25/2022 | $37,906 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA225955 | Exploring Collateral Lethality for Development of Cancer Therapeutics | 000 | 5 | NIH | 3/21/2022 | $426,406 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R35GM126929 | The molecular and genetic bases of diverse tissue repair responses in postembryonic Drosophila | 000 | 5 | NIH | 3/18/2022 | $359,998 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA214954 | Activating p53 for colorectal cancer prevention | 000 | 5 | NIH | 6/10/2022 | $33,593 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01DE027445 | Viral Replication Pathways During Oral Tumorigenesis and Response to Therapy | 000 | 6 | NIH | 12/21/2021 | $346,275 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01DE027445 | Viral Replication Pathways During Oral Tumorigenesis and Response to Therapy | 001 | 6 | NIH | 5/4/2022 | $34,628 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | U54CA224065 | University of Texas PDX Development and Trial Center | 000 | 4 | NIH | 6/17/2022 | $199,970 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | K01AR072132 | Dissect stress response in skin epithelial wounding and hyperproliferative disorders | 000 | 6 | NIH | 3/16/2022 | $134,655 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01GM124043 | Regulation of Cell Turnover During Epithelial Tissue Homeostasis | 000 | 5 | NIH | 3/4/2022 | $302,400 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA247992 | Targeting ferroptosis in radioresistance in lung cancer: mechanisms and preclinical translation | 001 | 2 | NIH | 5/20/2022 | $31,464 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA247992 | Targeting ferroptosis in radioresistance in lung cancer: mechanisms and preclinical translation | 000 | 2 | NIH | 11/22/2021 | $353,973 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA223772 | Cytoplasmic cyclin E is an early event for progression to invasive breast cancer | 001 | 5 | NIH | 5/19/2022 | $31,522 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA223772 | Cytoplasmic cyclin E is an early event for progression to invasive breast cancer | 000 | 5 | NIH | 1/13/2022 | $354,637 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA225977 | Immunotherapeutic Modalities for K-ras Mutant Lung Cancer: Sex- and Cell Type-Specific Roles of IL-6/STAT3 signaling | 001 | 5 | NIH | 5/25/2022 | $29,261 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA225977 | Immunotherapeutic Modalities for K-ras Mutant Lung Cancer: Sex- and Cell Type-Specific Roles of IL-6/STAT3 signaling | 000 | 5 | NIH | 3/25/2022 | $329,173 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA220236 | Wnt/?-catenin Signaling in Pancreatic Oncogenesis | 000 | 5 | NIH | 5/13/2022 | $358,680 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA231521 | A Combination Therapy to Treat Cancer-Related Fatigue | 001 | 4 | NIH | 5/19/2022 | $38,842 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA231521 | A Combination Therapy to Treat Cancer-Related Fatigue | 000 | 4 | NIH | 11/24/2021 | $436,954 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA204665 | Genomics of HCC in the Hispanic population of Texas | 001 | 5 | NIH | 5/19/2022 | $28,856 |
|
